PBLA vs. OGEN, ARTL, MBIO, HOTH, TRVN, GTBP, ONCO, BCEL, PHAS, and PTIX
Should you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Oragenics (OGEN), Artelo Biosciences (ARTL), Mustang Bio (MBIO), Hoth Therapeutics (HOTH), Trevena (TRVN), GT Biopharma (GTBP), Onconetix (ONCO), Atreca (BCEL), PhaseBio Pharmaceuticals (PHAS), and Protagenic Therapeutics (PTIX). These companies are all part of the "pharmaceutical products" industry.
Oragenics (NYSE:OGEN) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
Oragenics has higher revenue and earnings than Panbela Therapeutics. Oragenics is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.
Panbela Therapeutics' return on equity of -615.16% beat Oragenics' return on equity.
Oragenics has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500.
Panbela Therapeutics has a consensus price target of $500.00, suggesting a potential upside of 147,828.99%. Given Oragenics' higher probable upside, analysts plainly believe Panbela Therapeutics is more favorable than Oragenics.
18.7% of Oragenics shares are owned by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are owned by institutional investors. 24.6% of Oragenics shares are owned by insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Oragenics had 1 more articles in the media than Panbela Therapeutics. MarketBeat recorded 1 mentions for Oragenics and 0 mentions for Panbela Therapeutics. Panbela Therapeutics' average media sentiment score of 0.00 equaled Oragenics'average media sentiment score.
Panbela Therapeutics received 18 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 64.29% of users gave Panbela Therapeutics an outperform vote while only 0.00% of users gave Oragenics an outperform vote.
Summary
Oragenics and Panbela Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Panbela Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Panbela Therapeutics Competitors List
Related Companies and Tools
